Pay in 4 interest-free payments of $6.39 Learn more
Ships within 48 hours · Estimated delivery Jul 26 - Jul 31
Spontaneous reports cannot prove causation or incidence
The combination has not shown any emergent toxicity beyond what would be expected from either peptide individually
When you inject peptides like BPC 157 over the area of pain, it does not directly go to the area of tissue damage initially
Methods: In this post hoc analysis of the Alteplase compared to Tenecteplase (AcT) Trial, patients who underwent CTP and had either large vessel occlusion (LVO) or medium vessel occlusion (MeVO) were included
Composition BPC-157: 10 mg Appearance: Lyophilized powder in a sealed research vial Research Focus (non-clinical) Peptide identity and purity assessment via HPLC/LC-MS Assay development and calibration for quantitative analysis Chromatographic method optimization for impurity profiling Stability characterization of a lyophilized peptide under laboratory storage conditions Documentation Lot-specific COA available (HPLC/LC-MS) Batch and lot traceability Important Notice For research use only Not for human consumption Not intended to diagnose, treat, cure, or prevent any disease Quality & Manufacturing Lot-specific COA (HPLC/LC-MS) with verification key Third-party verification link provided per lot (Janoshik) Lyophilized for transit stability
